Vilhelmas Bajoras 🇱🇹🇺🇦🌻 (@vbajoras) 's Twitter Profile
Vilhelmas Bajoras 🇱🇹🇺🇦🌻

@vbajoras

🇱🇹 Interventional cardiologist. Trained in structural heart interventions @Rigshospitalet 🇩🇰. Board of @ltmedfootball.

ID: 1273394406

linkhttps://www.linkedin.com/in/vilhelmas-bajoras-827b50a3/ calendar_today16-03-2013 22:03:55

1,1K Tweet

393 Followers

979 Following

Dr. Gilbert Tang (@gilberttangmd) 's Twitter Profile Photo

Finally on my YouTube channel! #MitraClp G4 step-by-step device demo on this playlist: youtube.com/playlist?list=…. Will upload a full lecture on how to optimize efficiency & MR reduction soon! DoctorKini @Khera_MD Lucy Parasuram Krishnamoorthy MD RTHahnMD Syed Zaid, MD American College of Cardiology PCRonline 🫀

Finally on my <a href="/YouTube/">YouTube</a> channel! #MitraClp G4 step-by-step device demo on this playlist: youtube.com/playlist?list=…. Will upload a full lecture on how to optimize efficiency &amp; MR reduction soon! <a href="/DoctorKini/">DoctorKini</a> @Khera_MD <a href="/LucySafi/">Lucy</a> <a href="/ParasuramMD/">Parasuram Krishnamoorthy MD</a> <a href="/hahn_rt/">RTHahnMD</a> <a href="/SyedZaidMD/">Syed Zaid, MD</a> <a href="/ACCinTouch/">American College of Cardiology</a> <a href="/PCRonline/">PCRonline 🫀</a>
Davide Capodanno (@dfcapodanno) 's Twitter Profile Photo

A quick recap of new randomized trials in the fields of coronary and valvular interventions you may have missed this year at #EuroPCR if you were only watching live cases or attending practical sessions.

Davide Capodanno (@dfcapodanno) 's Twitter Profile Photo

Everything we have learned so far about the revascularization of non-culprit lesions in patients with acute myocardial infarction and multivessel disease... in 1 minute.

Salvatore Brugaletta (@sbrugaletta) 's Twitter Profile Photo

what I like most from 18th EBC consensus: keep things simple and limit number of stents. knowledge of anatomy is essential so please stop starting by default with DK Crush, which should be restricted to very few anatomical scenarios EuroIntervention eurointervention.pcronline.com/article/percut…

what I like most from 18th EBC consensus: keep things simple and limit number of stents. knowledge of anatomy is essential so please stop starting by default with DK Crush, which should be restricted to very few anatomical scenarios <a href="/EuroInterventio/">EuroIntervention</a> eurointervention.pcronline.com/article/percut…
Salvatore Brugaletta (@sbrugaletta) 's Twitter Profile Photo

I would add - DO NOT READ your slides!it is very annoying as everyone has already read everything so we do not need to hear again % of events in groups. - STOP making copy & paste of tables. the size is very small and none will read it. PCRonline 🫀 #europcr

Brandon Luu, MD (@brandonluumd) 's Twitter Profile Photo

This is one of the largest meta-analyses on the effects of exercise on cognitive performance. Here are my top 4 evidence-based protocols from it to leverage exercise to maximize cognitive performance. 1/13

This is one of the largest meta-analyses on the effects of exercise on cognitive performance.

Here are my top 4 evidence-based protocols from it to leverage exercise to maximize cognitive performance.
1/13
Jay Mohan, D.O., FACC, FSCAI, FASE, RPVI (@drjaymohan) 's Twitter Profile Photo

I almost always use a figure of 8 to close 8F to 24F venous access sites. I haven’t had any major issues and I still send many patients home same day. I’ve been tempted to move to perclose but not sure the real benefit. Anyone using perclose routinely on venous closure?

Davide Capodanno (@dfcapodanno) 's Twitter Profile Photo

Here’s my guide to navigate the #ACC25 trials, coming this weekend and featured in many journals with a (very) high impact factor. 1. WARRIOR = Intensive medical therapy in women with ANOCA/INOCA 2. STRIDE = Semaglutide in type 2 diabetes and peripheral artery disease 3. API-CAT

Here’s my guide to navigate the #ACC25 trials, coming this weekend and featured in many journals with a (very) high impact factor.

1. WARRIOR = Intensive medical therapy in women with ANOCA/INOCA
2. STRIDE = Semaglutide in type 2 diabetes and peripheral artery disease
3. API-CAT
Davide Capodanno (@dfcapodanno) 's Twitter Profile Photo

First day at #ACC25, here are the results of 10 trials presented today. I counted 3 NEJM, 1 Lancet, and 1 JAMA. WARRIOR: Intensive medical therapy did not reduce major CV events at five years in women with suspected INOCA. STRIDE: Semaglutide improved walking distance, symptoms,

First day at #ACC25, here are the results of 10 trials presented today. I counted 3 NEJM, 1 Lancet, and 1 JAMA.

WARRIOR: Intensive medical therapy did not reduce major CV events at five years in women with suspected INOCA.
STRIDE: Semaglutide improved walking distance, symptoms,
Shikha Jha M.D.🫀 (@shikha_cardio) 's Twitter Profile Photo

ACC 2025 LATE BREAKING CLINICAL TRIALS - One LINER SUMMARY 📸 AT A GLANCE ⭐️ What a phenomenal scientific meeting! Congratulations to all the presenters &research leaders for yet another fantastic year of innovation & research. 🫀❤️ 😊 #ACC2025 American College of Cardiology UW-Madison Division of Cardiovascular Medicine CardioNerds

ACC 2025  LATE BREAKING CLINICAL TRIALS - One LINER SUMMARY 📸 AT A GLANCE ⭐️ What a phenomenal scientific meeting! Congratulations to all the presenters &amp;research leaders for yet another fantastic year of innovation &amp; research. 🫀❤️ 😊 #ACC2025 <a href="/ACCinTouch/">American College of Cardiology</a> <a href="/uw_cvm/">UW-Madison Division of Cardiovascular Medicine</a> <a href="/CardioNerds/">CardioNerds</a>